Das, Shreyasee
van Engelen, Marie-Paule E.
Goossens, Julie
Jacobs, Dirk
Bongers, Bram
Fieldhouse, Jay L. P.
Pijnenburg, Yolande A. L.
Teunissen, Charlotte E.
Vanmechelen, Eugeen
Verberk, Inge M. W.
Funding for this research was provided by:
European Union's Horizon 2020 research and innovation Marie Curie program ‘MIRIADE’ (860197, 860197, 860197)
Stichting Alzheimer Nederland
Stichting Dioraphte
ZonMW-funded PRODIA project (#ZonMW 733050206)
Stichting VUmc
Article History
Received: 22 September 2023
Accepted: 4 February 2024
First Online: 14 February 2024
Declarations
:
: All clinical CSF samples were requested via the Amsterdam Dementia Cohort biobank. The study was approved by the Medical Ethical Committee of Amsterdam University Medical Center. All participants provided informed consent and the study has been carried out by the Declaration of Helsinki.
: Not applicable.
: S.D., and J.G., are employees of ADx NeuroSciences, Gent, Belgium. E.V. is the co-founder of ADx NeuroSciences. D.J. is a former employee of ADx NeuroSciences, Gent, Belgium, and is recently retired. C.E.T. has a collaboration contract with ADx NeuroSciences, Quanterix, and Eli Lilly, and has performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is the editor of a Neuromethods book Springer. All the other authors declare that they have no competing interests.